AVITA MED LTD/S (NASDAQ:RCEL) Reaches New 12-Month High at $9.80

AVITA MED LTD/S ADR (NASDAQ:RCEL) reached a new 52-week high during trading on Friday . The stock traded as high as $9.80 and last traded at $9.80, with a volume of 2326 shares trading hands. The stock had previously closed at $9.60.

Several research firms have recently commented on RCEL. Lake Street Capital upped their price target on shares of AVITA MED LTD/S from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. ValuEngine downgraded AVITA MED LTD/S from a “hold” rating to a “sell” rating in a research note on Friday, November 1st.

The company has a market cap of $778.29 million, a PE ratio of -24.87 and a beta of 1.28.

AVITA MED LTD/S Company Profile (NASDAQ:RCEL)

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.

Recommended Story: Consumer behavior in bull markets

Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.